Clario's Precision Motion Opal® technology powers University of Oxford breakthrough in Parkinson's Disease

Clario Denmark Finland France Germany Netherlands Sweden United Kingdom Pennsylvania England

Clario's Precision Motion Opal® wearable sensor technology detects early Parkinson's disease (PD) progression in a University of Oxford study funded by UCB Pharma.Digital endpoints of gait and balance, captured during a 2-Minute Walk test and 30-second Sway test, identify significant motor symptom progression more rapidly than conventional clinical rating scales.Earlier detection supported by state-of-the-art sensor technology and machine learning is a promising discovery to aid in the expedited development of effective PD treatments.View original content:https://www.prnewswire.co.uk/news-releases/clarios-precision-motion-opal-technology-powers-university-of-oxford-breakthrough-in-parkinsons-disease-301969111.html